Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 173,912 | 102,660 | 335,966 | 180,995 |
| Operating expenses: | ||||
| Cost of sales | 12,113 | 6,237 | 21,509 | 11,448 |
| Research and development | 31,010 | 15,594 | 53,361 | 30,003 |
| Selling, general and administrative | 150,697 | 103,013 | 287,126 | 188,008 |
| Total operating expenses | 193,820 | 124,844 | 361,996 | 229,459 |
| Loss from operations before other income (expense) | (19,908) | (22,184) | (26,030) | (48,464) |
| Other income (expense): |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s R&D?
- Tarsus Pharmaceuticals, Inc. (TARS) reported R&D of $31.01M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s R&D increased by 98.9% year-over-year, from $15.59M to $31.01M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s R&D has grown at a 11.4% compound annual growth rate (CAGR), from $41.71M to $64.32M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude